Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma This study is currently recruiting participants. Purpose To determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naïve, Stage IIIB/IV Non-Small Cell Lung Cancer Study Type:  Interventional Study Design:  Treatment, Open-Label, Single Group Assignment, Safety Study Official Title: A Phase 1b, Open-Label, Dose-Escalation Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Treatment-Naïve, Stage IIIB/IV Non-Small Cell Lung Cancer Further study details as provided by Biogen Idec: Primary Outcome Measures: To evaluate the safety and tolerability of BIIB022 in combination with paclitaxel and carboplatin [Time Frame: 6 months] [Designated as safety issue: Yes]   Estimated Enrollment:   18 Study Start Date:   October 2009 Estimated Study Completion Date:   May 2011 Estimated Primary Completion Date:   November 2010 (Final data collection date to primary outcome measure)   Arms Assigned Interventions BIIB022 in Combination with Paclitaxel and Carboplatin Experimental    BIIB022 in Combination with Paclitaxel and Carboplatin Drug: BIIB022 With Paclitaxel and Carboplatin    Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin Eligibility Ages Eligible for Study:   18 Years and older Genders Eligible for Study:   Both Accepts Healthy Volunteers:   No Criteria Inclusion Criteria: Age ≥ 18 years old Treatment-naïve Stage IIIB/IV Non-Small Cell Lung Cancer ECOG Performance Status 0 or 1 Exclusion Criteria: History of another primary cancer within 3 years Any prior or concurrent investigational or standard therapy for treatment of NSCLC Prior anti-IGF-1R therapy Unstable disease Please refer to: www.biogenideconcology.com Please refer to the clinicaltrials.gov website for further details on the study: http://www.clinicaltrials.gov/ct2/show/NCT00970580 To contact Biogen, click here.